Month: April 2024

Notable Labs Reports 2023 Financial Results and Provides a Business Update

Written by Customer Service on April 12, 2024. Posted in Earnings Releases And Operating Results.

FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December 31, 2023 and provided a business update. “The last year has been a time of great accomplishment for Notable. We built a strong clinical validation dataset, starting with a poster presented at the American Association for Cancer Research (AACR 2023); became a publicly listed company, following the closing of a reverse merger in October 2023; and reported successful PPMP clinical data from the Phase 2 fosciclopirox study that showcased the ability of our platform to accurately predict patient outcomes for specific therapeutics,”...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on April 12, 2024. Posted in Earnings Releases And Operating Results.

In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline, unblinded data from the full dataset expected at the end of 2024. Phase 2 proof-of-concept trial of farudodstat in alopecia areata (the FAST-AA study) has recruited close to 75% of patients; topline data readout expected in Q3 2024. Positive opinion received from European Patent Office on new patent application of farudodstat with potential to extend protection until at least 2043.SAN MATEO, Calif. and SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals...

Form 8.3 – [SPIRENT COMMUNICATIONS PLC – 11 04 2024] – (CGAML)

Written by Customer Service on April 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree SPIRENT COMMUNICATIONS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 11 04 2024] – (CGWL)

Written by Customer Service on April 12, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Progressive Reports March 2024 Results

Written by Customer Service on April 12, 2024. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, April 12, 2024 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended March 31, 2024 and the first quarter of 2024: March Quarter (millions, except per share amounts and ratios; unaudited) 2024 2024 2023 ChangeNet premiums written $ 7,746.0 $ 18,962.2 $ 16,109.7 18 %Net premiums earned $ 5,633.5 $ 16,148.6 $ 13,533.1 19 %Net income $ 893.6 $ 2,331.4 $ 447.9 421 %Per share available to common shareholders $ 1.52 $ 3.94 $ 0.75 425 %Total pretax net realized gains (losses) on securities $ 58.3 $ 155.6 $ 71.8 117 %Combined ratio 84.3 86.1 99.0 (12.9) pts.Combined ratio – prior year month 106.2 Average diluted equivalent common shares 587.4 587.3 587.0 0 %In...

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

Written by Customer Service on April 12, 2024. Posted in Public Companies.

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024. Details of the fireside chat are as follows: Date: Wednesday, April 17, 2024 Time: 10 a.m. ET Location: Presentation Track 1 Webcast: Available in the Events section of Ocugen website During the fireside chat and one-on-one sessions, Dr. Musunuri will showcase the Company’s recent business and clinical development progress including FDA clearance to initiate...

Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is Cancelled

Written by Customer Service on April 12, 2024. Posted in Public Companies.

NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) — Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship with Evome as an example of its willingness to fund growth companies: Evome Medical Technologies enjoys multi-year expansion with financing from Pathward Web link:https://www.pathward.com/news/evome-medical-technologies-enjoys-multi-year-expansion-with-fina/ This focus on revenue growth and market expansion has led the Company’s operating...

Invivyd Announces CEO Transition

Written by Customer Service on April 12, 2024. Posted in Public Companies.

Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO. Mr. Gowler succeeds Dave Hering. “The Invivyd Board of Directors is positioning the company for its next phase of growth,” said Marc Elia, Chairperson. “Invivyd is poised to lead a brand-new paradigm in delivering novel, impactful monoclonal antibody (mAb) therapies for the pre-exposure prophylaxis (PrEP) of COVID-19, and we wish to fully unlock this capability and associated value creation. In the interim, we...

AppTech Payments Corp. Announces 2024 Annual Shareholder Meeting

Written by Customer Service on April 12, 2024. Posted in Public Companies.

CARLSBAD, Calif., April 12, 2024 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech”) (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce, announced today it filed its proxy statement and will hold its Annual Shareholder Meeting on May 29, 2024, at 10:00 AM PST. To enable shareholders to attend regardless of their location, AppTech will hold the meeting virtually. Meeting details and instructions to access proxy materials have been disseminated to shareholders of record via direct mail in accordance with the notice and access model. Shareholders of record as of the April 5, 2024, record date are entitled to the notice of the Annual Meeting or any adjournment thereof. If you are a shareholder and have not received notice by May 1, 2024, please contact AppTech to obtain meeting details. About AppTech Payments...

Coop Pank AS will hold an investor webinar to introduce the results for the Q1 2024

Written by Customer Service on April 12, 2024. Posted in Public Companies.

Coop Pank invites shareholders, investors, analysts and other stakeholders to join its investor webinar, scheduled on 18 April 2024 at 9 am (EET). The webinar will be held in Estonian. The webinar will be hosted by the Chairman of the Board Margus Rink and the Chief Financial Officer Paavo Truu, who present the unaudited financial results of the First Quarter of 2024. During the webinar all attendees can ask questions. All questions will be answered after the presentation. To join the webinar, you need to register in advance via following link: https://bit.ly/CP-180424-registreerimine Registrants will be sent a link to the webinar and a reminder email one hour before the start of the webinar. The webinar will be recorded and published on the company’s website www.cooppank.ee and on our YouTube account. Coop Pank, based on Estonian...

Month: April 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals